Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T4032 vs Lumigan in Glaucoma and Ocular Hypertension
NCT03825380Phase 3Completed
- Sponsor
- Laboratoires Théa
- Start
- Nov 2018
- Primary completion
- Feb 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Intra-Ocular Pressure at 12 weeks. Started Nov 2018; status: completed.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT03825380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03825380.